MPY2

MPY2 appears to be a **specific experimental amino-pyrimidine-curcumin analog** reported in a medicinal chemistry study of stabilized pyrimidine-curcumin derivatives with potential anticancer activity. Based on the provided source, it is a **small-molecule, preclinical research compound** designed to improve on curcumin's poor stability and bioavailability while retaining anti-proliferative effects in cancer cell models. The disclosed series was evaluated in vitro in prostate and colorectal cancer cell lines, but the exact molecular target, developer, clinical development program, and any formal pharmaceutical development status for MPY2 specifically are not established from the provided evidence.